IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 325 filers reported holding IONIS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.84 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $506,537 | +85.8% | 11,167 | +68.1% | 0.00% | – |
| Q2 2023 | $272,645 | +10.5% | 6,645 | -3.7% | 0.00% | – |
| Q1 2023 | $246,678 | -5.6% | 6,902 | -0.2% | 0.00% | – |
| Q4 2022 | $261,254 | -18.4% | 6,917 | -4.6% | 0.00% | -100.0% |
| Q3 2022 | $320,000 | +24.0% | 7,247 | +3.8% | 0.00% | – |
| Q2 2022 | $258,000 | +210.8% | 6,979 | +208.4% | 0.00% | – |
| Q1 2022 | $83,000 | +38.3% | 2,263 | +15.7% | 0.00% | – |
| Q4 2021 | $60,000 | -11.8% | 1,956 | -2.8% | 0.00% | – |
| Q3 2021 | $68,000 | +11.5% | 2,012 | +31.7% | 0.00% | – |
| Q2 2021 | $61,000 | -29.1% | 1,528 | -21.2% | 0.00% | – |
| Q1 2021 | $86,000 | +22.9% | 1,939 | +55.7% | 0.00% | – |
| Q4 2020 | $70,000 | +18.6% | 1,245 | +1.1% | 0.00% | – |
| Q3 2020 | $59,000 | 0.0% | 1,231 | +22.4% | 0.00% | – |
| Q2 2020 | $59,000 | -16.9% | 1,006 | -33.7% | 0.00% | – |
| Q1 2020 | $71,000 | +29.1% | 1,518 | +69.6% | 0.00% | – |
| Q4 2019 | $55,000 | -40.9% | 895 | -42.8% | 0.00% | – |
| Q3 2019 | $93,000 | -7.0% | 1,564 | +0.4% | 0.00% | – |
| Q2 2019 | $100,000 | -17.4% | 1,558 | +4.9% | 0.00% | -100.0% |
| Q1 2019 | $121,000 | +68.1% | 1,485 | +12.1% | 0.00% | – |
| Q4 2018 | $72,000 | +4.3% | 1,325 | -0.3% | 0.00% | – |
| Q3 2018 | $69,000 | +13.1% | 1,329 | -9.1% | 0.00% | – |
| Q2 2018 | $61,000 | -4.7% | 1,462 | 0.0% | 0.00% | – |
| Q1 2018 | $64,000 | +60.0% | 1,462 | +82.3% | 0.00% | – |
| Q4 2017 | $40,000 | -2.4% | 802 | -0.7% | 0.00% | – |
| Q3 2017 | $41,000 | +78.3% | 808 | +76.0% | 0.00% | – |
| Q2 2017 | $23,000 | +35.3% | 459 | +6.7% | 0.00% | – |
| Q1 2017 | $17,000 | -62.2% | 430 | -54.2% | 0.00% | – |
| Q4 2016 | $45,000 | +18.4% | 938 | -42.2% | 0.00% | -100.0% |
| Q2 2016 | $38,000 | -33.3% | 1,622 | +14.5% | 0.00% | 0.0% |
| Q1 2016 | $57,000 | +21.3% | 1,417 | +88.7% | 0.00% | 0.0% |
| Q4 2015 | $47,000 | – | 751 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tweedy, Browne Co LLC | 3,541,136 | $133,749 | 7.12% |
| Bellevue Group AG | 9,743,900 | $368,027,103 | 4.88% |
| M28 Capital Management LP | 126,300 | $4,770,351 | 4.55% |
| Sicart Associates LLC | 246,258 | $9,301,165 | 3.28% |
| Camber Capital Management LP | 1,925,000 | $72,707 | 2.49% |
| Privium Fund Management B.V. | 148,807 | $5,557,941 | 2.11% |
| Deep Track Capital, LP | 1,205,773 | $45,542,046 | 1.91% |
| BVF INC/IL | 1,121,809 | $42,370,726 | 1.79% |
| Orbimed Advisors | 1,993,600 | $75,298,272 | 1.44% |
| Parkman Healthcare Partners LLC | 141,115 | $5,329,914 | 1.42% |